Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Quest Diagnostics Posts Profit In Q1; Lifts Annual Earnings Forecast

RELATED NEWS
Trade DGX now with 

Quest Diagnostics Inc. (DGX: Quote) on Wednesday reported a profit for its first quarter, compared to prior year's loss, benefited by the non-recurring of last year's hefty charge related to California's Medicaid program. Adjusted earnings increased from last year on higher revenues. Further, the provider of diagnostic testing, information and services lifted its fiscal 2012 adjusted earnings forecast, while maintained revenue growth forecast.

Surya Mohapatra, Chairman and CEO, said, "Quest Diagnostics had a very solid first quarter. We saw strong growth in esoteric and advanced gene-based testing as a result of our focus on cancer, cardiovascular disease, infectious disease and neurological disorders. In addition, we saw improved growth in routine testing."

For its first quarter, net income attributable to company was $159.1 million or $0.99 per share, compared to a loss of $53.9 million or $0.33 per share in the year ago quarter.

The latest quarter results were hurt by $0.08 per share charges related to restructuring and integration activities as well as CEO succession costs. The prior year's results were hurt by $1.33 per share charge mainly related to Medi-Cal, California's Medicaid program, and other special items.

Adjusted income from continuing operations, which excluded items, grew 7 percent to $171 million or $1.07 per share from $164 million or $1 per share last year. On average, 22 analysts polled by Thomson Reuters expected the company to report earnings of $1.01 per share. Analysts' estimates typically exclude special items.

Net revenues increased 6.3 percent to $1.94 billion from $1.82 billion in the prior year, driven by both organic growth and acquisitions and beat analysts' consensus estimate of $1.88 billion. The acquisitions of Athena, Celera and SED contributed 3.2 percent to consolidated revenue growth.

In the quarter, clinical testing revenues increased 6.4 percent driven by higher revenue per requisition and volume, measured by the number of requisitions.

The extreme weather in last year's first quarter contrasted with the unseasonably mild weather this year is estimated to have benefited the revenue and volume comparisons by approximately 2 percent, the company noted.

For the first quarter, operating margin surged to 15.5 percent from 1.7 percent last year, and adjusted operating margin increased to 16.5 percent from 16.3 percent a year ago.

Quest added that it is making good progress in its previously announced $500 million cost reduction initiative, aimed at improving operational efficiency.

Looking ahead for fiscal 2012, the company now expects adjusted earnings from continuing operations to be between $4.45 and $4.60 per share, higher than previous range of $4.40 to $4.55 per share. Analysts expect the company to report earnings of $4.54 per share.

On a reported basis, full-year earnings would be between $4.37 and $4.52 per share.

Meanwhile, the company continues to expect revenues to grow between 2 percent and 2.5 percent.

Quest shares are currently trading at $62.27 in pre-market activity, up $1.98 or 3.28 percent.

Register
To receive FREE breaking news email alerts for Quest Diagnostics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Policymakers of Reserve Bank of Australia decided to maintain its record low interest rate once again as they continue to assess that the most prudent course is a period of stability in interest rates. The monetary policy board retained the cash rate at 2.50 percent. The rate has been at the current level since August 2013. A ban on athletes using stamina-boosting gases - xenon and argon - came into effect on Monday. The World Anti-Doping Agency (WADA) said Hypoxia-Inducible Factor (HIF) activators Xenon and Argon have been added to the 2014 List of Prohibited Substances and Methods List following the required three-month notice period and UNESCO's communication to all States Parties. A recommendation to revise the British manufacturing growth eased further in August to its lowest level in 14 months as output and demand increased at slower rates, survey results from Markit Economics showed Monday. The Markit/CIPS Purchasing Managers' Index dropped to 52.5 from a revised 54.8 in July. Economists had expected the score to fall to 55.1 from July's original figure of 55.4.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.